Alumis Inc., a late-stage biopharma company specializing in next-generation targeted therapies for immune-mediated diseases, has successfully completed its merger with ACELYRIN, Inc. This strategic move establishes a leading clinical-stage biopharma company with a robust portfolio and a strong financial position. As part of the merger, ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock for each ACELYRIN share they own. With this merger, Alumis aims to advance its pipeline and extend its cash runway into 2027, ensuring continued development of transformative therapies for patients.